The majority of ovarian cancers are not attributed to hereditary germlinemutations in the BRCA1 and 2 genes (Venkitaraman, 2002), so a key question is whether single-agentPARP inhibitors can be used to treat patients within the larger ovarian cancerpopulation. This evidence concerns the gene BRCA1 and ovarian carcinoma.